Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells

Table 1 Characteristic of patients

No.	Age/sex	Diagnose	WBC (10⁹/L)	HGB (g/L)	PLT (10⁹/L)	BCR/ABL	Treatment	Time of disease (month)	Survival
P1	43 Y/M	CML-CP	290	72	931	Positive	Imatinib	11	Yes
P2	42 Y/F	CML-CP	282	77	673	Positive	Imatinib	11	Yes
P3	32 Y/F	CML-CP	34	131	505	Positive	Imatinib	10	Yes
P4	33 Y/M	CML-CP	165	85	396	Positive	Dasatinib	10	Yes
P5	27 Y/M	CML-CP	288	68	560	Positive	Imatinib	9	Yes
P6	63 Y/M	CML-AP	320	77	887	Positive	Imatinib	21	No

P patient; Y year; M male; F female; CML-CP chronic myelogenous leukemia-chronic phase; CML-AP chronic myelogenous leukemia-acute phase; WBC white blood cells; HGB hemoglobin; PLT platelet

ISSN: 1479-5876